Initiation of pivotal Phase 3 trial in non-small cell lung cancer (NSCLC) marks the first landmark in BioNTech’s and OncoC4’s…
The company’s single sign-on and identity governance solutions helped Health and Social Care (HSC) Trust onboard 500 personnel in under…
Primary Endpoint of Safety and Efficacy Endpoint Both Met with Clinical Activity and Increased Survival Observed 70.3 Weeks Median Overall…
Results support comparability of cosibelimab 800 mg every-two-week and 1200 mg every-three-week dosing regimens Biologics License Application for cosibelimab under…
PHILADELPHIA and VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”…
Ocean Biomedical’s Inclusion in the Russell 2000® Index and Russell 3000® Index Builds Momentum for Cutting Edge Therapeutic Programs Targeting…
MDNA11 demonstrates durable single-agent activity in forth-line metastatic pancreatic cancer patient with a partial response continuing for over 40 weeks…
Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company…
Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),…
Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features, using a modified lymphodepletion incorporating…